Abstract. Protein regulator of cytokinesis‐1 (PRC1) is a microtubule‐associated factor involved in cytokinesis. Recent studies have indicated that PRC1 overexpression is involved in tumorigenesis in multiple types of human cancer. However, the expression, biological functions and the prognostic sign
H. Bu,Yingwei Li,Chengjuan Jin,Hongfeng Yu,Xiangxiang Wang,Jingying Chen,Yu Wang,Makoto Yana,Youzhong Zhang,B. Kong
2020-01-01
Abstract:Protein regulator of cytokinesis‐1 (PRC1) is a microtubule‐associated factor involved in cytokinesis. Recent studies have indicated that PRC1 overexpression is involved in tumorigenesis in multiple types of human cancer. However, the expression, biological functions and the prognostic signifi‐ cance of PRC1 in ovarian cancer have not yet been clarified. In this study, it was confirmed that the PRC1 mRNA and protein expression levels were upregulated in high‐grade serous ovarian carcinoma (HGSOC) tissues, particularly in patients without breast cancer susceptibility gene (BRCA) pathogenic mutations. PRC1 overexpression contributed to drug resistance, tumor recurrence and a poor prognosis. The findings also indicated that PRC1 knockdown decreased the proliferation, metastasis and multidrug resistance of ovarian cancer cells in vitro. It was also demonstrated that forkhead box protein M1 (FOXM1) regulated the mRNA and protein expression of PRC1. Dual‐luciferase reporter assay and rescue assay confirmed that PRC1 was a direct crucial downstream target of FOXM1. On the whole, the findings of this study confirmed that PRC1 was a major prognostic factor of HGSOC and a promising therapeutic biomarker for the treatment of ovarian cancer. Introduction Epithelial ovarian cancer is a fatal gynecological malignancy, resulting in 295,414 new cases and 184,799 deaths worldwide in 2018 (1), exhibiting an upward trend (1,2). High‐grade serous ovarian carcinoma (HGSOC) is the most common subtype (70%) associated with a higher degree of malignancy and a poorer prognosis (3). However, the molecular pathogenesis, the mechanisms of molecular regulation and drug resistance associated with HGSOC remain poorly characterized. Protein regulator of cytokinesis‐1 (PRC1), also known as Ase1 (yeast)/MAP65 (plant), was first identified as a CDK substrate in 1998 and was known as an essential microtubule associated protein required for cytokinesis via the phos‐ phorylation of CDK1 (Cdc2/cyclin B) in early mitosis (4,5). Previous studies have found that cells in which PRC1 is knocked down can normally undergo interphase, prophase, prometaphase and metaphase, and chromatin can be equally distributed in the anaphase of mitosis; however, the structure of the central area of the spindle appears to be abnormal at anaphase, leading to the aberrant expression of cytokines and the formation of binuclear or multinucleated cells (5,6). Therefore, an abnormal expression of PRC1 can lead to aber‐ rant cytokine expression, contributing to tumorigenesis and tumor progression. It has already been demonstrated that PRC1 is upregu‐ lated in various types of tumor, such as hepatocellular carcinoma (7), gastric carcinoma (8) and pulmonary adenocarcinoma (9,10). The overexpression of PRC1 has been shown to significantly promoted the proliferation and metastasis of hepatocellular carcinoma cells, and to be associated with early recurrence and a poor patient outcome by regulating the oncogenic effects of the Wnt signaling pathway (7). The knockdown of PRC1 has also been shown to significantly suppress the proliferation, reduce monolayer colony formation and to inhibit the invasive and migratory ability of gastric carcinoma cells (8). To date, however, at least to the best of our knowledge, the expression, biological functions and prognosis significance of PRC1 in ovarian cancer have not yet been elucidated. Overexpression of PRC1 indicates a poor prognosis in ovarian cancer HUALEI BU1,2*, YINGWEI LI3*, CHENGJUAN JIN4, HONGFENG YU5, XIANGXIANG WANG1,2, JINGYING CHEN1,2, YU WANG1,2, YANA MA1,2, YOUZHONG ZHANG1,2 and BEIHUA KONG1,2 1Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University; 2Key Laboratory of Gynecologic Oncology of Shandong Province; 3School of Medicine, Shandong University, Jinan, Shandong 250012; 4Department of Obstetrics and Gynecology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201620; 5Department of Obstetrics and Gynecology, Zhenjiang First People's Hospital, Zhenjiang, Jiangsu 212000, P.R. China Received May 19, 2019; Accepted November 11, 2019 DOI: 10.3892/ijo.2020.4959 Correspondence to: Dr Youzhong Zhang or Dr Beihua Kong, Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhua Xi Road, Jinan, Shandong 250012,